Core Viewpoint - The stock of Chunli Medical (688236) has shown a positive trend with a closing price of 15.76 yuan, reflecting a 4.03% increase on May 6, 2025, amidst varying capital flows from different investor groups [1]. Financial Performance - Chunli Medical reported a main revenue of 230 million yuan for Q1 2025, representing a year-on-year increase of 3.6% [2]. - The net profit attributable to shareholders was 58.07 million yuan, up 5.2% year-on-year, while the net profit after deducting non-recurring gains and losses was 52.70 million yuan, increasing by 7.81% [2]. - The company has a debt ratio of 17.11% and reported investment income of 3.22 million yuan, with financial expenses of -4.17 million yuan [2]. Market Position - Chunli Medical's total market capitalization is 6.045 billion yuan, with a net asset value of 2.879 billion yuan [2]. - The company ranks 47th in total market value and 52nd in net assets within the medical device industry [2]. - The price-to-earnings ratio (P/E) stands at 26.02, significantly lower than the industry average of 52.22, placing it 33rd in the industry ranking [2]. Profitability Metrics - The gross margin for Chunli Medical is 66.69%, which is higher than the industry average of 51.09%, ranking 27th in the industry [2]. - The net profit margin is 25.25%, compared to the industry average of 10.86%, ranking 28th [2]. - The return on equity (ROE) is 2.04%, outperforming the industry average of 1.06%, ranking 43rd [2]. Investor Sentiment - In the last 90 days, 8 institutions have rated the stock, with 7 buy ratings and 1 hold rating, indicating positive investor sentiment [3]. - The average target price set by institutions over the past 90 days is 17.59 yuan [3].

Group 1 - The core viewpoint of the articles highlights that Chunli Medical's stock price has increased by 4.03% to 15.76 yuan, with a rolling PE ratio of 47.28, marking a new low in 140 days, and a total market capitalization of 6.045 billion yuan [1][2] - Chunli Medical ranks 87th in the medical device industry based on PE ratio, with the industry average at 48.90 and the median at 36.41 [1][2] - As of the first quarter of 2025, 13 institutions hold shares in Chunli Medical, including 8 funds, with a total holding of 31.6307 million shares valued at 429 million yuan [1] Group 2 - Chunli Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with key products including spinal, trauma, joint, sports medicine implants, and surgical instruments [1] - The company achieved a revenue of 230 million yuan in the first quarter of 2025, reflecting a year-on-year growth of 3.60%, and a net profit of 58.0711 million yuan, with a year-on-year increase of 5.20% and a gross margin of 66.69% [1]

Investment Rating - The investment rating for the company is "Buy" [6][4]. Core Views - The company has shown stable growth in Q1 2025, with revenue, net profit attributable to the parent, and net profit excluding non-recurring items reaching 230 million, 58 million, and 53 million RMB respectively, representing year-on-year increases of 3.6%, 5.2%, and 7.8% [1]. - The rapid growth of overseas revenue has become a significant source of income, with overseas revenue in 2024 reaching 350 million RMB, a year-on-year increase of 78.3%, accounting for 43.8% of total revenue [2]. - The company is expected to recover its performance growth in 2025, driven by improvements in domestic business and continued expansion in overseas markets [2]. Summary by Sections Financial Performance - In Q1 2025, the company maintained a gross margin of 66.69%, although it decreased by 7.15 percentage points year-on-year due to the impact of centralized procurement [3]. - The company has successfully controlled its sales and R&D expense ratios, which decreased year-on-year [3]. Profit Forecast - The profit forecast for the company estimates net profits attributable to the parent company for 2025, 2026, and 2027 to be 240 million, 290 million, and 340 million RMB respectively, with growth rates of 90%, 21%, and 20% [4]. - The estimated EPS for 2025, 2026, and 2027 is projected to be 0.62, 0.75, and 0.90 RMB respectively [4]. Valuation - The company is assigned a target price of 18.59 RMB for A-shares and 11.34 HKD for H-shares, based on a PE valuation of 30x for A-shares and 17x for H-shares in 2025 [4][6].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 229,843,941.53, representing a 3.60% increase compared to CNY 221,850,180.79 in the same period last year[4]. - Net profit attributable to shareholders was CNY 58,071,117.89, up 5.20% from CNY 55,199,616.28 year-on-year[4]. - The net profit excluding non-recurring gains and losses was CNY 52,698,123.38, reflecting a 7.81% increase from CNY 48,882,462.10 in the previous year[4]. - Basic and diluted earnings per share were both CNY 0.15, an increase of 7.14% from CNY 0.14 in the same quarter last year[4]. - Total operating revenue for Q1 2025 reached CNY 229,843,941.53, an increase of 3.4% compared to CNY 221,850,180.79 in Q1 2024[18]. - Net profit for Q1 2025 was CNY 58,030,577.70, representing a 3.5% increase from CNY 55,107,063.21 in Q1 2024[19]. - Earnings per share for Q1 2025 were CNY 0.15, up from CNY 0.14 in Q1 2024[20]. Research and Development - Total R&D investment amounted to CNY 26,897,460.32, a decrease of 23.13% from CNY 34,991,868.71 in the previous year, with R&D expenses accounting for 11.70% of operating revenue, down from 15.77%[4]. - Research and development expenses for Q1 2025 totaled CNY 26,897,460.32, down from CNY 34,991,868.71 in Q1 2024[18]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 3,473,532,404.39, a slight increase of 0.22% from CNY 3,465,734,982.98 at the end of the previous year[5]. - The total current liabilities decreased from RMB 227,845,174.60 to RMB 198,903,468.21, a reduction of approximately 12.7%[16]. - The company's total liabilities decreased to CNY 594,157,689.89 from CNY 644,390,846.18 year-over-year[18]. - The total equity attributable to shareholders increased to CNY 2,877,973,401.17 from CNY 2,819,902,283.28[18]. Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of CNY -75,343,585.60 compared to CNY -129,613,339.07 in the same period last year[4][9]. - Cash flow from operating activities in Q1 2025 was CNY 154,928,044.70, a decrease from CNY 211,271,503.82 in Q1 2024[21]. - Operating cash inflow totaled $160,007,655.13, a decrease from $217,425,731.31 year-over-year[22]. - Operating cash outflow amounted to $235,351,240.73, down from $347,039,070.38 year-over-year[22]. - Net cash flow from operating activities was -$75,343,585.60, compared to -$129,613,339.07 in the previous year[22]. - Cash and cash equivalents at the end of the period were $1,796,034,364.28, compared to $1,220,123,829.78 at the end of the previous year[23]. - The net increase in cash and cash equivalents was $657,016,713.62, contrasting with a decrease of $45,889,245.89 in the prior year[23]. Shareholder Information - The company reported a total of 7,182 ordinary shareholders, with 7,167 holding A shares and 15 holding H shares[14]. - The top ten shareholders include Beijing Panmao Investment Management Co., Ltd. with 17,250,000 shares, representing a significant stake in the company[14]. - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[15]. Other Information - The company received government subsidies amounting to CNY 1,038,221.69, which are closely related to its normal business operations[6]. - Non-recurring gains and losses totaled CNY 5,372,994.51 after tax and minority interest adjustments[7]. - The company has not disclosed any significant new strategies or product developments during the reporting period[15]. - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[23].

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock closed at 14.28 yuan, down 3.32%, with a rolling PE ratio of 43.82 times and a total market value of 5.477 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Chunzhi Medical at the 85th position in the industry ranking [1] - As of the 2024 annual report, four institutions hold shares in Chunzhi Medical, with a total of 382,700 shares valued at 0.05 million yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest performance report for 2024 shows that the company achieved operating revenue of 806 million yuan, a year-on-year decrease of 33.32%, and a net profit of 125 million yuan, down 55.01%, with a gross profit margin of 66.63% [1]

证券代码：688236 证券简称：春立医疗 公告编号：2025-015 北京市春立正达医疗器械股份有限公司 关于设立募集资金专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 经上海证券交易所科创板股票上市委员会审核同意，并根据中国证券监督管 理委员会出具证监许可〔2021〕3702号同意注册文件，北京市春立正达医疗器械股 份有限公司（以下简称"公司"）获准向社会公众公开发行人民币普通股（A股） 股票38,428,000股，每股面值人民币1.00元，发行价格为每股人民币29.81元，募集 资金总额为人民币114,553.87万元。扣除发行费用（不含增值税）后，募集资金净 额为106,712.83万元。上述募集资金到位情况经大信会计师事务所（特殊普通合伙） 审验，并由其出具《验资报告》（大信验字[2021]第3-00041号）。 公司已对募集资金采取了专户存储，并按规定与保荐机构、专户存储募集资 金的相关银行签署了募集资金专户监管协议。监管协议对公司、保荐机构及存放 募集资金相关银行的相关责任和义务进 ...

4月16日，春立医疗今日收盘13.25元，下跌1.56%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到40.66倍，总市值50.82亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.94倍，行业中值29.64倍，春立医疗排 名第86位。 股东方面，截至2025年2月28日，春立医疗股东户数6666户，较上次减少247户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)86春立医疗40.6640.661.8050.82亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819 ...

尊敬的各位投资者和广大支持春梨医疗的伙伴朋友们大家上午好欢迎大家参加春梨医疗2024年度业绩及现金分红说明会很高兴和大家进行互动交流我是春梨医疗董事会秘书谢凤榜首先非常感谢上海证交所上证路演中心为公司搭建这样一个与投资者交流的平台 增加公司向资本市场展示的机会增进投资者对公司的了解及时传递公司的投资价值接下来请允许我介绍出席本次会议的公司管理层他们分别是春丽医疗董事长史文林女士春丽医疗总经理史春生先生春丽医疗财务总监李玉梅女士 今天我们的业绩说明会将会分为两个部分首先是由公司管理层致辞对公司2024年业务发展情况及现金分红情况做详细的介绍然后针对投资者关心的问题和大家进行互动希望今天的业绩及现金分红说明会能够让大家进一步了解春利医疗的经营情况和投资价值 首先有请公司董事长史文林女士致辞尊敬的各位投资者朋友大家上午好欢迎大家参加春粒医疗2024年度业绩及现金分红说明会我是公司董事长史文林首先我仅代表公司董事会管理层以及公司全体员工向一直以来关心支持与帮助我们的朋友表示感谢 春利医疗是国内领先的骨科医疗器械企业主营业务是植入性骨科医疗器械的研发、生产与销售主要产品包括关节、脊柱、运动医学以及创伤产品公司在关节领域 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 董事會會議通告 代表董事會 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國，北京，2025年4月15日 截至本公告日期，執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；非執行 董事為王鑫先生；及獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此 宣佈將於2025年4月29日（星期二）舉行董事會會議，藉以（其中包括）批准本公 司及其附屬公司截至2025年3月31日止三個月之第一季度業績公佈及考慮派付 中期股息（如有）。 ...

华泰联合证券有限责任公司 关于北京市春立正达医疗器械股份有限公司 2024 年年度持续督导跟踪报告 经公司自查及保荐机构督导发现，公司在 2023 年 10 月 30 日至 2024 年 1 月 16 日、2024 年 1 月 18 日至 2024 年 3 月 11 日存在使用闲置募集资金进行现 金管理的额度超出了第五届董事会第五次会议授权额度的情形，在此期间公司进 行现金管理的最高额度为 70,500 万元，超出董事会授权使用额度 5,500 万元。 公司董事会及监事会已对上述使用闲置募集资金进行现金管理超过授权额 度的情形进行补充确认。截至 2024 年 12 月 31 日，公司使用闲置募集资金进行 现金管理的余额为 61,900 万元，符合董事会授权的额度要求。 保荐机构已于 2024 年 3 月 28 日就上述事项出具《华泰联合证券有限责任公 司关于北京市春立正达医疗器械股份有限公司使用及追认部分闲置募集资金进 行现金管理额度暨增加现金管理额度的核查意见》，并督促发行人进一步加强募 1 集资金的管理工作，确保募集资金的使用、决策程序及信息披露合法合规。 二、重大风险事项 | 保荐机构名称： | 被保荐 ...